James F. Demarest
About
In The Last Decade
James F. Demarest
46 papers receiving 4.9k citations
Hit Papers
Peers
Comparison fields: 5 of 108
- Virology 3.9k
- Immunology 2.7k
- Infectious Diseases 2.0k
- Epidemiology 1.2k
- Molecular Biology 418
Countries citing papers authored by James F. Demarest
This map shows the geographic impact of James F. Demarest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James F. Demarest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James F. Demarest more than expected).
Fields of papers citing papers by James F. Demarest
This network shows the impact of papers produced by James F. Demarest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James F. Demarest. The network helps show where James F. Demarest may publish in the future.
Co-authorship network of co-authors of James F. Demarest
This figure shows the co-authorship network connecting the top 25 collaborators of James F. Demarest. A scholar is included among the top collaborators of James F. Demarest based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James F. Demarest. James F. Demarest is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Title | Journal | Authors | Indexed citations |
|---|---|---|---|---|
| 1 | Antiviral target compound profile for pandemic preparedness | Nature Reviews Drug Discovery | James F. Demarest, Ruxandra Draghia‐Akli et al. | 1 |
| 2 | An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral | Antiviral Research | Justin G. Julander, James F. Demarest et al. | 53 |
| 3 | Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection | AIDS Research and Human Retroviruses | Marta Boffito, Laura Waters et al. | 28 |
| 4 | First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study. | PubMed | Jayvant Heera, Srinivas Rao Valluri et al. | 1 |
| 5 | Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance | AIDS Research and Human Retroviruses | James F. Demarest, Mark Underwood et al. | 16 |
| 6 | First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN | Journal of the International AIDS Society | Jayvant Heera, Srinivas Rao Valluri et al. | 5 |
| 7 | Comparison of Population and 454 “Deep” Sequence Analysis for HIV Type 1 Tropism Versus the Original Trofile Assay in Non-B Subtypes | AIDS Research and Human Retroviruses | Guinevere Q. Lee, P. Richard Harrigan et al. | 14 |
| 8 | Use of Cellular HIV DNA to Predict Virologic Response to Maraviroc: Performance of Population-Based and Deep Sequencing | Clinical Infectious Diseases | Luke C. Swenson, Winnie Dong et al. | 24 |
| 9 | Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078 | Antiviral Research | Simon Portsmouth, Srinivas Rao Valluri et al. | 7 |
| 10 | HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry | AIDS Research and Human Retroviruses | John C. Tilton, Heather Amrine‐Madsen et al. | 44 |
| 11 | In Vitro and Clinical Investigation of the Relationship Between CCR5 Receptor Occupancy and Anti‐HIV Activity of Aplaviroc | The Journal of Clinical Pharmacology | James F. Demarest, Kathleen Schell et al. | 10 |
| 12 | Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals | AIDS | David M. Irlbeck, Heather Amrine‐Madsen et al. | 19 |
| 13 | Immunologic and Virologic Analyses of an Acutely HIV Type 1-Infected Patient with Extremely Rapid Disease Progression | AIDS Research and Human Retroviruses | James F. Demarest, Noreen Jack et al. | 18 |
| 14 | Accumulation of human immunodeficiency virus‐specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection | European Journal of Immunology | Giuseppe Pantaleo, Hugo Soudeyns et al. | 35 |
| 15 | Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection breakdown → | New England Journal of Medicine | Giuseppe Pantaleo, Stefano Menzo et al. | 562 |
| 16 | Role of Lymphoid Organs in the Pathogenesis of Human Immunodeficiency Virus (HIV) Infection | Immunological Reviews | Giuseppe Pantaleo, Cecilia Graziosi et al. | 143 |
| 17 | Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV breakdown → | Nature | Giuseppe Pantaleo, James F. Demarest et al. | 503 |
| 18 | Expression of a wide T cell receptor Vβ repertoire in human T lymphocytes derived in vitro from embryonic liver cell precursors | European Journal of Immunology | Alessandro Poggi, James F. Demarest et al. | 4 |
| 19 | HIV-1 infection in the lymphoid organs | AIDS | Cecilia Graziosi, G Pantaleo et al. | 24 |
| 20 | HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease breakdown → | Nature | Giuseppe Pantaleo, Cecilia Graziosi et al. | 1452 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.